Chondrocyte-Targeting Nanoparticles for Low-Inflammation Gene Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing viral vectors for gene therapy in osteoarticular disorders induce inflammatory responses and have limitations such as toxicity, immune response, and limited packaging capacity, while non-viral systems lack specificity and efficiency in targeting chondrocytes.
Innovation Solution
Development of nanoparticles comprising a cargo, lipid component, and targeting peptide, specifically designed for chondrocytes, which are self-assembled and provide enhanced resistance to nuclease digestion, allowing targeted and efficient delivery of therapeutic agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If viral vectors are used for gene delivery to chondrocytes, then transfection efficiency is improved, but inflammatory response and immune reaction worsen
Solution Approach 1:
The patent uses non-viral nanoparticles as disposable, transient delivery vehicles that achieve gene delivery without the persistent immune activation and inflammatory responses associated with viral vectors. These nanoparticles are designed to be temporary, non-replicating systems that complete their delivery function and are cleared without causing long-term harm.
Solution Approach 2:
The patent introduces targeting peptides as intermediary components that mediate specific binding to chondrocyte surface markers (such as CD44, TLR4, or COMP). This intermediary mechanism enables selective delivery to cartilage cells without the non-specific inflammatory activation caused by viral vectors, bridging the gap between non-viral safety and viral targeting efficiency.
2Productivity
If viral vectors are used for gene delivery, then delivery efficiency is improved, but toxicity and immune response worsen
Solution Approach 1:
The patent employs non-viral nanoparticle systems that are inherently less toxic and immunogenic than viral vectors. These disposable delivery vehicles achieve their function without the replication-Associated toxicity and persistent immune responses of viral systems, providing a safer alternative for repeated dosing.
Solution Approach 2:
The patent creates composite nanoparticle structures combining lipid or polymer cores with conjugated targeting peptides. This composite design integrates the biocompatibility and low toxicity of non-viral materials with the targeted delivery capability of peptide ligands, achieving efficient delivery without viral-associated toxicity.
3Object-generated harmful factors
If non-viral delivery systems are used, then immune response is reduced, but targeting specificity and efficiency worsen
Solution Approach 1:
The patent introduces targeting peptides as intermediary components that mediate specific binding to chondrocyte surface markers (such as CD44, TLR4, or COMP). This intermediary mechanism enables selective delivery to cartilage cells without the non-specific inflammatory activation caused by viral vectors, bridging the gap between non-viral safety and viral targeting efficiency.
Solution Approach 2:
The patent applies local quality by concentrating targeting functionality at the nanoparticle surface through peptide conjugation. The surface-localized peptides provide specific recognition of chondrocyte markers, while the core nanoparticle material maintains biocompatibility. This spatial differentiation of functions achieves both targeting precision and immune tolerance.
4Quantity of substance
If viral vectors are used, then gene delivery capacity is improved, but packaging capacity limitations worsen
Solution Approach 1:
The patent exploits parameter changes in nanoparticle design, particularly the scalable size and composition of lipid or polymer nanoparticles, to accommodate varying cargo loads. Unlike viral vectors with fixed capsid capacities, these synthetic nanoparticles can be adjusted in size, charge, and composition to optimize packaging for different therapeutic payloads including siRNA, mRNA, or plasmid DNA.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The nanoparticles offer improved targeting and reduced immune response, enabling larger cargo delivery with enhanced transfection efficiency and selectivity for chondrocytes, suitable for treating joint diseases like osteoarthritis.
Implementation Method 1
nanoparticles comprising a cargo, lipid component, and targeting peptide, which are self-assembled
Data Source
AI summary
Nanoparticles suitable for delivery of a cargo to a chondrocyte, and targeting peptides comprising a chondrocyte targeting sequence, are provided. Further provided are uses of the nanoparticles and targeting peptides, for example, in treating a joint or cartilage disease or disorder.